PBI 4050

Drug Profile

PBI 4050

Alternative Names: PBI-4050

Latest Information Update: 22 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProMetic Life Sciences
  • Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Skin disorder therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase modulators; Autophagy stimulants; Cell differentiation modulators; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; FFAR1 protein modulators; GPR84 protein modulators; Immunomodulators; Inflammation mediator inhibitors; MTOR protein modulators; PPAR-alpha-modulators; Protein serine threonine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alstrom's Syndrome; Inborn genetic disorders; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alstrom's Syndrome
  • Phase II Cystic fibrosis; Diabetic nephropathies; Idiopathic pulmonary fibrosis; Metabolic syndrome; Scleroderma; Type 2 diabetes mellitus
  • Preclinical Acute lung injury; Pulmonary hypertension; Renal fibrosis
  • No development reported Anaemia; Haematological disorders; Neutropenia

Most Recent Events

  • 17 Oct 2018 ProMetic Life Sciences terminates a phase II trial in Metabolic syndrome in patients with Type-2 diabetes mellitus due to failure to meet recruitment target within the recruitment period in Canada (NCT03081598)
  • 07 Aug 2018 PBI 4050 receives rare paediatric disease designation for Alstrom's Syndrome from the US FDA
  • 17 Jul 2018 ProMetic Pharma initiates a phase I trial in Healthy volunteers in USA (NCT03637049)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top